These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25599446)

  • 21. A cross-sectional study on prevalence of pain and breakthrough pain among an unselected group of outpatients in a tertiary cancer clinic.
    Raj SX; Thronaes M; Brunelli C; Hjermstad MJ; Klepstad P; Kaasa S
    Support Care Cancer; 2014 Jul; 22(7):1965-71. PubMed ID: 24595408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breakthrough pain: characteristics and impact in patients with cancer pain.
    Portenoy RK; Payne D; Jacobsen P
    Pain; 1999 May; 81(1-2):129-34. PubMed ID: 10353500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study.
    Portenoy RK; Messina J; Xie F; Peppin J
    Curr Med Res Opin; 2007 Jan; 23(1):223-33. PubMed ID: 17207304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fentanyl buccal tablet.
    Messina J; Darwish M; Fine PG
    Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breakthrough pain in patients with controlled or uncontrolled basal pain: an observational study.
    Gatti A; Gentili M; Baciarello M; Lazzari M; Marzi R; Palombo E; Sabato AF; Fanelli G
    Pain Res Manag; 2014; 19(6):e168-71. PubMed ID: 24945289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain.
    Webster LR; Messina J; Xie F; Nalamachu S
    J Opioid Manag; 2011; 7(4):297-308. PubMed ID: 21957829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
    Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
    Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of opioid rotation in the control of cancer pain: the ROTODOL study.
    González-Barboteo J; Alentorn XG; Manuel FA; Candel VA; Eito MA; Sánchez-Magro I; Álvarez MN; Martín FJ; Porta-Sales J
    J Opioid Manag; 2014; 10(6):395-403. PubMed ID: 25531957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is it possible to detect an improvement in cancer pain management? A comparison of two Norwegian cross-sectional studies conducted 5 years apart.
    Thronæs M; Raj SX; Brunelli C; Almberg SS; Vagnildhaug OM; Bruheim S; Helgheim B; Kaasa S; Knudsen AK
    Support Care Cancer; 2016 Jun; 24(6):2565-74. PubMed ID: 26712631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breakthrough cancer pain: an observational study of 1000 European oncology patients.
    Davies A; Buchanan A; Zeppetella G; Porta-Sales J; Likar R; Weismayr W; Slama O; Korhonen T; Filbet M; Poulain P; Mystakidou K; Ardavanis A; O'Brien T; Wilkinson P; Caraceni A; Zucco F; Zuurmond W; Andersen S; Damkier A; Vejlgaard T; Nauck F; Radbruch L; Sjolund KF; Stenberg M
    J Pain Symptom Manage; 2013 Nov; 46(5):619-28. PubMed ID: 23523361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circadian variation of breakthrough pain in cancer patients.
    Saini A; Tucci M; Tampellini M; Maina D; Bouraouia K; Giuliano PL; Termine A; Castellano M; Campagna S; Laciura P; Berruti A
    Eur J Pain; 2013 Feb; 17(2):264-70. PubMed ID: 22715071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options.
    Mercadante S
    Curr Opin Anaesthesiol; 2015 Oct; 28(5):559-64. PubMed ID: 26263120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Procedural Pain in Palliative Care: Is It Breakthrough Pain? A Multicenter National Prospective Study to Assess Prevalence, Intensity, and Treatment of Procedure-related Pain in Patients With Advanced Disease.
    Magnani C; Giannarelli D; Casale G
    Clin J Pain; 2017 Aug; 33(8):707-714. PubMed ID: 27768607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of cancer-induced bone pain: an exploratory study.
    Laird BJ; Walley J; Murray GD; Clausen E; Colvin LA; Fallon MT
    Support Care Cancer; 2011 Sep; 19(9):1393-401. PubMed ID: 20680354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. End-of-dose pain in chronic pain: does it vary with the use of different long-acting opioids?
    Zimmermann M; Richarz U
    Pain Pract; 2014 Nov; 14(8):757-69. PubMed ID: 24373184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.
    Yen TY; Chiou JF; Chiang WY; Su WH; Huang MY; Hu MH; Wu SC; Lai YL
    Medicine (Baltimore); 2018 Jul; 97(30):e11593. PubMed ID: 30045291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and characteristics of breakthrough pain in patients receiving opioids for chronic back pain in pain specialty clinics.
    Bennett DS; Simon S; Brennan M; Shoemaker SA
    J Opioid Manag; 2007; 3(2):101-6. PubMed ID: 17520989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical effectiveness and safety of OROS® hydromorphone in break-through cancer pain treatment: a multicenter, prospective, open-label study in Korean patients.
    Lee KH; Kim MK; Hyun MS; Kim JY; Park KU; Song HS; Lee SA; Lee WS; Bae SH; Ryoo HM; Cho YY
    J Opioid Manag; 2012; 8(4):243-52. PubMed ID: 22941852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The treatment of breakthrough pain.
    McCarberg BH
    Pain Med; 2007; 8 Suppl 1():S8-13. PubMed ID: 17280601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology: A 12-month Open-label Study in Patients with Chronic Pain.
    Hale ME; Zimmerman TR; Ma Y; Malamut R
    Pain Pract; 2017 Feb; 17(2):229-238. PubMed ID: 26857424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.